3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Breast Diseases
1
Interventions
Cisplatin
98
pembrolizumab
79
Radiotherapy
49
Carboplatin
41
Magnetic Resonance Spectroscopy
37
toripalimab
34
Radiotherapy, Intensity-Modulated
34
Gemcitabine
29
Docetaxel
28
Cetuximab
28
Specimen Handling
26
Surgical Procedures, Operative
23
Paclitaxel
23
Fluorouracil
22
Radiation
20
Nivolumab
20
Biopsy
18
Drug Therapy
17
Chemoradiotherapy
17
Blood Specimen Collection
17
Capecitabine
15
Standard of Care
14
tislelizumab
13
Surveys and Questionnaires
13
Platinum
13
camrelizumab
12
nimotuzumab
11
Immune Checkpoint Inhibitors
11
130-nm albumin-bound paclitaxel
11
1,2-diaminocyclohexaneplatinum II citrate
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Imlunestrant
×
Head & Neck
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled